PCSK9 and atherosclerosis: In line with the preliminary outcomes of the ATHEROREMO-IVUS study, the randomized GLAGOV (Global Assessment of Plaque Regression with PCSK9 Antibody as Measured by Intravascular Ultrasound) trial supported the effect of PCSK9 inhibitors on atherosclerosis regression in patients who do not achieve a reduction in cardiovascular events or an adequate LDL-C decrease in spite of optimal statin treatment.